16.80
-0.47(-2.72%)
Currency In USD
Address
116 Huntington Avenue
Boston, MA 02116
United States of America
Phone
617-468-4219
Website
Sector
Healthcare
Industry
Biotechnology
Employees
55
First IPO Date
September 13, 2024
| Name | Title | Pay | Year Born |
| Claire Mazumdar Clemon | Chief Executive Officer & Director | 829,800 | 1989 |
| Ryan Cohlhepp | President, Chief Operating Officer & Director | 825,750 | 1977 |
| Ivan Hyep | Chief Financial Officer | 915,375 | 1985 |
| David Raben | Chief Medical Officer | 0 | 1963 |
| Jeltje Schulten | Senior Vice President of Clinical & Medical Affairs | 0 | N/A |
| Angela Windt | Vice President & Head of Regulatory Affairs | 0 | N/A |
| Lara S. Meisner | Chief Legal Officer & Corporate Secretary | 0 | 1973 |
| Pauline Dufresne | Chief People Officer | 0 | N/A |
| Rachel Salazar | SVP of R&D Strategy and Operations | 0 | N/A |
| Sathish Hasige | Senior Vice President and Head of Technical Operations & Supply Chain | 0 | N/A |
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.